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Abstract
Introduction: Recently, we reported that high levels of resistin are present in the peripheral blood of patients with
intracerebral hemorrhage and are associated with a poor outcome. However, not much is known regarding the
change in plasma resistin and its relation with mortality after traumatic brain injury (TBI). Thus, we sought to
investigate change in plasma resistin level after TBI and to evaluate its relation with disease outcome.
Methods: Fifty healthy controls and 94 patients with acute severe TBI were included. Plasma samples were
obtained on admission and at days 1, 2, 3, 5 and 7 after TBI. Its concentration was measured by enzyme-linked
immunosorbent assay.
Results: Twenty-six patients (27.7%) died from TBI within 1 month. After TBI, plasma resistin level in patients
increased during the 6-hour period immediately after TBI, peaked within 24 hours, plateaued at day 2, decreased
gradually thereafter and was substantially higher than that in healthy controls during the 7-day period. A forward
stepwise logistic regression selected plasma resistin level (odds ratio, 1.107; 95% confidence interval, 1.014-1.208;
P = 0.023) as an independent predictor for 1-month mortality of patients. A multivariate linear regression showed
that plasma resistin level was negatively associated with Glasgow Coma Scale score (t = -6.567, P < 0.001). A
receiver operating characteristic curve identified plasma resistin cutoff level (30.8 ng/mL) that predicted 1-month
mortality with the optimal sensitivity (84.6%) and specificity (75.0%) values (area under curve, 0.854; 95% confidence
interval, 0.766-0.918; P < 0.001).
Conclusions: Increased plasma resistin level is found and associated with Glasgow Coma Scale score and mortality
after TBI.
Introduction
Resistin belongs to a novel family of cysteine-rich pro-
teins called resistin-like molecule or found in inflamma-
tory zones (FIZZ) proteins [1]. In rodents, resistin is
derived almost exclusively from adipose tissue [2] and
implicated as a factor linking obesity and diabetes by
impairing insulin sensitivity and glucose tolerance [3]. In
humans, resistin is expressed primarily in inflammatory
cells, especially macrophages [4]. Furthermore, resistin
has been shown to be involved in inflammatory pro-
cesses. Some proinflammatory agents, such as tumor
necrosis factor-a [5], interleukin-6 [6] and lipopolysac-
charide [7], can regulate resistin gene expression. Recent
studies have shown the regulation of proinflammatory
cytokine expression by resistin [8-10]. Moreover, resistin
is proposed as an inflammatory marker in human ather-
osclerosis [11] and rheumatoid arthritis [8].
However, it is evidenced that resistin could be pro-
duced by the brain and pituitary gland [12]. Furthermore,
resistin mRNA was increased in the cortex of hypoxic
and ischemic [13] and traumatic [14] animal brain. In the
patients with ischemic stroke, high plasma resistin level
has been associated with mortality and disability [15].
Recently, we reported that high levels of resistin are pre-
sent in the peripheral blood of patients with intracerebral
hemorrhage and are associated with poor outcome [16].
However, not much is known regarding change in plasma
resistin and its relation to mortality after traumatic brain
injury (TBI). Therefore, we examined changes in plasma
resistin levels in patients during the initial 7-day period
after TBI and also assessed its association with 1-month
mortality in a group of TBI patients.
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Materials and methods
Study population
Between March 2007 and April 2010, a total 119
patients with a postresuscitation Glasgow Coma Scale
(GCS) score of 8 or less were admitted to the Depart-
ment of Neurosurgery, Shengzhou People’s Hospital.
Exclusion criteria were less than 10 years of age, existing
previous neurological disease, head trauma, use of anti-
platelet or anticoagulant medication, presence of other
prior systemic diseases including uremia, liver cirrhosis,
malignancy, chronic heart or lung disease, diabetes mel-
litus, hyperlipidemia, obesity and hypertension. The
patients who suffered severe life-threatening injury to
other organs were also excluded. Finally, 94 patients
were included.
A control group consisted of 50 healthy age-and sex-
matched subjects with normal results on brain magnetic
resonance imaging and without vascular risk factors.
Informed consent to participate in the study was
obtained from them or their relatives. This protocol was
approved by the Ethics Committee before implementation.
Clinical and radiological assessment
On arrival to the emergency department, a detailed
history of vascular risk factors, concomitant medica-
tion, GCS score, pupil size and reactivity, body tem-
perature, heart rate, respiratory rate, blood oxygen
saturation and blood pressure was taken. Shock was
defined as systolic blood pressure less than 90 mmHg
[17]. Hypoxia was defined as blood oxygen saturation
less than 85% [17]. Hyperglycemia was defined as
blood glucose more than 11.1 mmol/L [18]. Hypogly-
cemia was defined as blood glucose less than 2.2
mmol/L [19]. Neurology deterioration was defined as
occurring in patients who manifested clinically identi-
fied episodes of one or more of the following: (1) a
spontaneous decrease in GCS motor score of 2 points
or more from the previous examination, (2) a further
loss of papillary reactivity, (3) development of papillary
asymmetry greater than 1 mm, or (4) deterioration in
neurological status sufficient to warrant immediate
medical or surgical intervention [17].
All computed tomography (CT) scans were performed
according to the neuroradiology department protocol.
Investigators who read them were blinded to clinical
information. Focal mass lesion, midline shift > 5 mm,
abnormal basal cisterns (compressed or absent cisterns)
and traumatic subarachnoid hemorrhage were recorded.
Focal mass lesions included contusion, subdural hema-
toma, epidural hematoma and intracerebral hematoma.
CT classification was performed using Traumatic Coma
Data Bank criteria on initial postresuscitation CT scan
according to the method of Marshall et al. [20].
Patient management
The treatments included surgical therapy, ventilatory
support, arterial pressure maintenance, glycemic control,
intravenous fluids, hyperosmolar agents, H2 blockers,
early nutritional support and physical therapy. The deci-
sion to intubate and use mechanical ventilation was
based on the individuals’ level of consciousness, ability
to protect their airway and arterial blood gas levels [21].
Adequate intravascular volume was pursued aggres-
sively, and vasopressors were used only after volume
expansion. When clinical and radiological examinations
provided an estimate of elevation of intracranial pres-
sure, osmotherapy in the form of intravenous mannitol
was administered, if available, deepening sedation and
hyperventilation. Hyperglycemia and hypoglycemia were
strictly avoided. Intracranial mass lesions associated with
midline displacement greater than 5 mm were surgically
removed when necessary. If intracranial pressure
remained high despite maximal medical therapy or after
intracranial mass lesion was removed, decompressive
craniectomy was performed as soon as possible.
Determination of resistin in plasma
The informed consents were obtained from the study
population or family members in all cases before the
blood was collected. In the control group, venous blood
was drawn at study entry. In the TBI patients, venous
blood was drawn on admission (defined as day 0) and at
8:00 AM at days 1, 2, 3, 5 and 7 after TBI. The blood
samples were immediately placed into sterile ethylene-
diaminetetraacetic acid test tubes and centrifuged at
1500 g for 20 minutes at 4°C to collect plasma. Plasma
was stored at -70°C until assayed. The concentration of
resistin in plasma was analyzed by enzyme-linked
immunosorbent assay using commercial kits (R&D Sys-
tems, Minneapolis, MN, USA) in accordance with the
manufacturer’s instructions.
End point
Outcome was assessed as mortality within 1 month.
Cause of death during the study for all patients was TBI.
Statistical analysis
All values are expressed as means ± standard deviation
(SD) unless otherwise specified. Statistical analysis was
performed with SPSS 10.0 software (SPSS Inc., Chicago,
IL, USA) and MedCalc 9.6.4.0 software (MedCalc Soft-
ware, Mariakerke, Belgium), and included the Mann-
Whitney U test, c2 test, Fisher’s exact test, Spearman
correlation coefficient, z statistic analysis, forward step-
wise logistic regression and multivariate linear regres-
sion. A receiver operating characteristic curve was
configured to establish the cutoff point of plasma
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resistin with the optimal sensitivity and specificity for
predicting 1-month mortality. A P value less than 0.05
was considered statistically significant.
Results
Patient characteristics
Ninety-four patients were enrolled in this study, namely,
67 men and 27 women. The mean age was 42.9 ± 18.6
years (range, 11-80 years). On admission, the mean GCS
score was 5.8 ± 1.8 (range, 3-8), the mean systolic arter-
ial pressure was 123.5 ± 29.5 mmHg (range, 50-180
mmHg), the mean diastolic arterial pressure was 73.9 ±
18.9 mmHg (range, 30-108 mmHg) and the mean arter-
ial pressure was 90.4 ± 21.5 mmHg (range, 38.0-124.7
mmHg). Fourteen (14.9%) patients suffered from shock,
18 (19.1%) patients had hyperglycemia, 3 (3.2%) patients
had hypoglycemia, 9 (9.6%) patients had hypoxia and 38
(40.4%) patients had unreactive pupils. Seventy-eight
patients (83.0%) need mechanical ventilation. On initial
CT scan, 34 (36.2%) patients had abnormal cisterns, 40
(42.6%) patients showed midline shift > 5 mm and 48
(51.1%) patients had the presence of traumatic subarach-
noid hemorrhage. After admission, 21 (22.3%) patients
presented with neurological deterioration. In the first 24
hours, 40 (42.6%) patients underwent intracranial sur-
gery. Forty-five (47.9%) patients had CT classification of
5 or 6. The mean admission time was 2.2 ± 1.4 hours
(range, 0.5-8.0 hours) after TBI. The mean plasma-sam-
pling time was 3.0 ± 1.4 hours (range, 1.0-8.4 hours)
after TBI. The baseline blood glucose level was 9.3 ± 3.2
mmol/L (range, 1.4-17.6 mmol/L). The baseline plasma
C-reactive protein, fibrinogen, D-dimer and resistin
levels were 7.7 ± 2.6 mg/L (range, 3.9-13.4 mg/L), 4.1 ±
2.0 g/L (range, 1.6-8.3 g/L), 2.2 ± 1.0 mg/L (range, 1.0-
4.9 mg/L) and 28.1 ± 12.2 ng/mL (range, 10.2-69.7 ng/
mL), respectively.
Serial change in plasma resistin level in patients with TBI
After TBI, plasma resistin level in patients increased
during the 6-hour period immediately, peaked within 24
hours, plateaued at day 2, decreased gradually thereafter
and was substantially higher than that in healthy con-
trols during the 7-day period (Figure 1).
Mortality prediction
Twenty-six patients (27.7%) died from TBI within 1
month. Baseline plasma resistin level in the nonsurvival
group was significantly higher than that in the survival
group (39.4 ± 12.4 vs. 23.8 ± 9.0 ng/mL; P < 0.001). The
neurological condition upon admission using GCS score
and unreactive pupils was statistically significantly differ-
ent (both P < 0.001) between the two groups. A higher
proportion of patients in the nonsurvival group suffered
from hyperglycemia (P = 0.003), had CT classification of
5 or 6 (P = 0.036) and required mechanical ventilation
(P = 0.007) compared with those in the survival group.
The brain CT scan results on admission were analyzed
and demonstrated a statistically significant difference
between the two groups in abnormal cisterns (P <
0.001), in midline shift > 5 mm (P = 0.001) and in the
presence of traumatic subarachnoid hemorrhage (P =
0.029). Blood glucose level (P = 0.038) and plasma C-
reactive protein (P = 0.007), fibrinogen (P = 0.015) and
D-dimer (P = 0.011) levels in the survival group were
significantly lower than those in the nonsurvival group
in the laboratory examination results on admission.
When the above variables found to be significant in
the univariate analysis were introduced into the logistic
model, multivariate analyses selected GCS (odds ratio,
0.294; 95% confidence interval, 0.153-0.565; P < 0.001)
and plasma resistin level (odds ratio, 1.107; 95% confi-
dence interval, 1.014-1.208; P = 0.023) as the indepen-
dent predictors for 1-month mortality of patients.
Correlations of plasma resistin level with GCS scores
A significant correlation emerged between GCS score
and plasma resistin level, as well as other variables
shown in Table 1. When the above variables were intro-
duced into the linear regression model, plasma resistin
level remained negatively associated with GCS score (t =
-6.567; P < 0.001).
The predictive significance of plasma resistin level for 1-
month mortality of patients
A receiver operating characteristic curve identified that a
plasma resistin level predicted 1-month mortality of TBI
patients with optimal sensitivity and specificity (Figure 2).
Discussion
Resistin is generally considered to be exclusively pro-
duced by adipose tissue [1]. Nevertheless, there is little
Figure 1 Graph showing serial changes of plasma resistin
concentration in traumatic brain injury (TBI) patients. Data are
expressed as means ± SD.
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doubt that the resistin gene is expressed in multiple
nonadipose sites. Resistin expression is abundant in the
brain and pituitary gland [12]. This abundance of nona-
dipose tissue sites for resistin expression has compli-
cated the original hypothesis that resistin might be an
important link between adipocytes and insulin resis-
tance. Recently, it was evidenced that resistin mRNA
was increased in the cortex of hypoxic/ischemic [13]
and traumatic [14] animal brain. This protein also
increases in the peripheral blood of patients with
ischemic [15] and hemorrhagic [16] stroke. These find-
ings suggest that resistin could contribute to the patho-
genesis of brain injury.
This study found increased plasma resistin level after
acute (< 6 hours) severe TBI in association with a worse
clinical outcome. It is well known that high plasma
resistin levels may be strongly associated with an
increased risk of 5-year mortality or disability after
atherothrombotic ischemic stroke [15] as well as related
to 1-week mortality after acute spontaneous basal gang-
lia hemorrhage [16]. To our knowledge, this is the first
time that the relationship of plasma resistin level with
outcome has been investigated soon after TBI in adults.
In this study, a low score on the GCS upon admission
was strongly correlated with a high plasma resistin level.
A multivariate analysis selected plasma resistin level as
an independent predictor of mortality. Overall, it was
suggested that plasma resistin level in this early period
might reflect the initial brain injury.
The present work is a single-institution study and has
the inherent limitations of any small series. As a conse-
quence, the conclusions in this study remain to be
verified.
Conclusions
In this study, increased plasma resistin level is found
and associated with GCS score and mortality after TBI.
Key messages
• In patients with traumatic brain injury, plasma resistin
level increased during the 6-hour period immediately,
peaked within 24 hours, plateaued at day 2, decreased
gradually thereafter and was substantially higher than
that in healthy controls during the 7-day period.
• Plasma resistin levels were highly associated with
GCS scores after traumatic brain injury.
• Resistin could possibly serve as a novel biomarker in
TBI.
• Plasma resistin level predicted 1-month mortality
after TBI with the high sensitivity and specificity values.
• Resistin may be a good prognostic factor for mortal-
ity in patients with TBI.
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Figure 2 Graph showing the predictive significance of plasma
resistin level for 1-month mortality of patients. Receiver
operating characteristic curve was analyzed by z statistic analysis.
Table 1 Baseline clinical, radiological and laboratory
factors correlated with plasma resistin level*
r value P value
GCS score on admission -0.547 0.000
Hyperglycemia on admission 0.333 0.001
Hypoxia on admission 0.286 0.005
Pupils unreactive on admission 0.521 0.000
CT classification 5 or 6 0.219 0.034
Abnormal cisterns on initial CT scan 0.344 0.001
Midline shift > 5 mm on initial CT scan 0.308 0.002
Mechanical ventilation 0.223 0.031
Blood glucose level (mmol/L) 0.241 0.019
Plasma C-reactive protein level (mg/L) 0.332 0.001
Plasma fibrinogen level (g/L) 0.281 0.006
Plasma D-dimer level (mg/L) 0.232 0.025
*Correlations of plasma resistin level with other variables were analyzed by
Spearman test. CT, computed tomography; GCS, Glasgow Coma Scale.
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